Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 6,941 shares at $23.12 ($158K) on 2011-02-18, disclosed to the SEC on 2011-02-23.
Scheduled sale ($158k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $23.12 | 3,701 | $86K | 54.0% |
| 2 | $22.50 | 3,240 | $73K | 46.0% |
| Total | $22.83 avg | 6,941 | $158K | 100% |
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2013-02-22 | $155K | — | Filing → |